TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
Provided By GlobeNewswire
Last update: Dec 9, 2024
To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0.14)
Read more at globenewswire.comNASDAQ:TCRX (9/26/2025, 2:36:41 PM)
1.84
+0.06 (+3.37%)
Find more stocks in the Stock Screener
